After decades of mostly unsuccessful R&D, Amgen has claimed the first ever ... The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting that combination therapy could become the new standard of care.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy ...

A new drug combination shows promise for colon cancer patients whose disease no longer responds to standard chemotherapy ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab.

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding ...

Amgen's first-in-class KRAS inhibitor Lumykras ... The MHRA has approved Lumykras (sotorasib) for patients with previously treated locally advanced or metastatic non-small cell lung cancer ...